Case Study: Janssen Pharmaceuticals achieves 99% reduction in compliance issues and faster publication submissions with BP Logix

Janssen Reduces Compliance Risks in Pharma Publication Planning

Janssen Pharmaceuticals, the pharmaceutical arm of Johnson & Johnson, was plagued by compliance and efficiency failures in its publication planning—missing debarment checks and authorship agreements, manual record extraction, costly integrations, and reliance on external agencies that left them at audit risk. To address this, Janssen turned to BP Logix and its low-code Process Director platform to replace the inadequate off-the-shelf system.

BP Logix configured Process Director to automate Janssen’s complex SOPs with pre-built components (Debarment Checks, Intelligent Review), always-on audit tracking, integrations, and process metrics via the Process Timeline. The BP Logix solution eliminated most manual compliance work (solving 99% of compliance issues), cut publication submission time from hours to minutes, removed the need for external compliance chase efforts, and delivered a total cost of ownership 50% lower than the predecessor.

Janssen Pharmaceuticals

Deirdre Bookman

Director of Global Commercial Strategy Operations